Prognostic Models for Predicting Overall Survival in Patients with Primary Gastric Cancer: A Systematic Review

Table 2

Final predictors included in the models.

Category	Number of predictors	Number of predictors selected multiple times	Predictors selected multiple times^a
Patient	21	9	Age, sex, ethnicity, performance score, year of diagnosis, family history, smoking, residency, and addiction to opium
Disease status	34	21	T stage, N stage, TNM stage, tumor site, tumor size, differentiation, metastasis, histologic type, Lauren type, LN ratio, lymphovascular invasion, bone metastasis, Borrmann type, liver metastasis, number of metastasis sites, lung metastasis, number of examined LN, metastasis LN, perineural invasion, LODDS, and TTP after chemotherapy
Biomarker	116	19	CEA, NLR, ALP, albumin, bilirubin, CA199, Hb, CES1, IS, LDH, LNR:ART, lymphocyte count, MGAT5, mGPS, NPTM, platelet, sodium, TNFRSF11A, and WBC
Treatment	9	6	Chemotherapy, gastrectomy, lymphedenectomy, resection margin, extent of resection, and radiotherapy

^aThe table lists only the predictors that have been included more than once. LN: lymph node. LODDS: log odds of positive LN. CEA: carcinoembryonic antigen. NLR: neutrophil/lymphocyte ratio. ALP: alkaline phosphatase. Hb: hemoglobin. MGAT5: β1, 6-N-acetylglucosaminyltransferase-5. mGPS: modified Glasgow Prognostic Score. CA199: cancer antigen 199. NPTM: number of positive tumor markers (cancer antigen 125, CA199, CEA). WBC: white blood cell. TTP: time to progression.